相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma
K. T. Siu et al.
LEUKEMIA (2017)
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
L. L. da Motta et al.
ONCOGENE (2017)
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
Irfan A. Asangani et al.
MOLECULAR CANCER RESEARCH (2016)
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Hemant K. Bid et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
Managing risks in drug discovery: reproducibility of published findings
Aimo Kannt et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2016)
Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice
Dong U. Lee et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
BET inhibition as a new strategy for the treatment of gastric cancer
Raquel C. Montenegro et al.
ONCOTARGET (2016)
Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function
Andre Kleensang et al.
SCIENTIFIC REPORTS (2016)
BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
Saeed Alghamdi et al.
STEM CELL RESEARCH & THERAPY (2016)
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhenfeng Zhang et al.
THERANOSTICS (2016)
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Alison M. Kurimchak et al.
Cell Reports (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
Elizabeth Wadhwa et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2016)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
Weilong Yao et al.
ONCOTARGET (2015)
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
Krishan Kumar et al.
Scientific Reports (2015)
Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Irawati Kandela et al.
ELIFE (2015)
Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives
Robert F. Shearer et al.
GENES TO CELLS (2015)
Standardised animal models of host microbial mutualism
A. J. Macpherson et al.
MUCOSAL IMMUNOLOGY (2015)
Inhibition of bromodomain and extraterminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence
Aristeidis Chaidos et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
An open investigation of the reproducibility of cancer biology research
Timothy M. Errington et al.
ELIFE (2014)
Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature
Kathleen M. Kokolus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo
Teemu D. Laajala et al.
CLINICAL CANCER RESEARCH (2012)
Replicates and repeats-what is the difference and is it significant? A brief discussion of statistics and experimental design
David L. Vaux et al.
EMBO REPORTS (2012)
Inhibition of Firefly Luciferase by General Anesthetics: Effect on In Vitro and In Vivo Bioluminescence Imaging
Marleen Keyaerts et al.
PLOS ONE (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals
Dan M. Close et al.
SENSORS (2011)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Timing of Imaging after D-Luciferin Injection Affects the Longitudinal Assessment of Tumor Growth Using In Vivo Bioluminescence Imaging
Yusuke Inoue et al.
INTERNATIONAL JOURNAL OF BIOMEDICAL IMAGING (2010)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab et al.
BLOOD (2009)
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission
Marleen Keyaerts et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?
Peyton Hughes et al.
BIOTECHNIQUES (2007)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
分享论文
